Garmin stock brings India ECG rollout into focus after higher outlook

Garmin Ltd. expanded its wearable-health offering in India during the week, while its raised 2026 outlook remained part of the investment debate. The developments give investors two angles on the company: wider use of health features and continued scrutiny of costs and segment mix.

ECG App reaches Indian users

Garmin activated its ECG App in India on November 3 for owners of the f?nix 9, Venu 4 and Forerunner 970, according to TechTimes. Users can record a 30-second, single-lead heart-rhythm trace and check for atrial fibrillation after updating Garmin Connect and the watch firmware.

The feature is available to compatible-device owners without an additional access fee. TechTimes reported that the app is intended to help identify possible atrial fibrillation and is not designed to detect heart attacks or replace medical evaluation.

Higher outlook meets cost pressure

A November 1 analysis by Simply Wall St, published by Yahoo Finance, focused on Garmin's record third quarter and higher full-year revenue guidance of about 8.15 billion US dollars. The analysis also pointed to pressure in Auto OEM and domain controllers, as well as rising memory costs and the need to sustain demand for premium products.

That combination leaves the Fitness and health ecosystem central to the investment case, but it does not remove execution risks. Investors will watch whether new hardware and software features support demand while weaker businesses and input costs weigh on margins.

Quote remains a live market reference

Garmin Ltd. stock traded at 256.30 euros on Lang & Schwarz at 11:46 CET on Saturday, November 7, 2026. Investors can follow the real-time quote of Garmin stock.

The S&P 500 offers the relevant market backdrop for a US-listed technology and wearable-health company; see current market coverage.

More Garmin-related developments are available in more news and analyses on Garmin stock.